differ
treatment
current
use
clinic
manag
infect
littl
known
efficaci
yet
present
ongo
result
compar
current
avail
drug
varieti
diseas
find
counteract
cytopath
effect
vitro
goal
priorit
antivir
activ
provid
solid
evidencedriven
rational
forthcom
clinic
trial
sinc
effect
antivir
approach
usual
base
combin
therapi
tackl
viral
life
cycl
differ
stage
also
test
combin
drug
may
critic
reduc
emerg
resist
virus
provid
result
soon
becom
avail
data
interpret
caution
clearli
understand
limit
vitro
model
may
alway
reflect
could
happen
vivo
thu
goal
test
activ
antivir
identifi
adequ
anim
model
infect
add
inform
possibl
vivo
efficaci
turn
success
antivir
could
test
clinic
trial
treatment
infect
patient
also
preexposur
prophylaxi
avoid
novel
infect
effect
safe
vaccin
develop
et
al
inhibit
infect
engin
human
tissu
use
clinicalgrad
solubl
human
cell
journal
preproof
novel
betacoronaviru
sever
acut
respiratori
syndrom
coronaviru
caus
larg
respiratori
outbreak
began
wuhan
china
novemb
spread
global
around
world
chen
et
al
date
approv
antivir
drug
specif
treatment
human
coronaviru
infect
howev
sever
drug
use
frontlin
clinic
manag
individu
hospit
around
world
avoid
develop
coronaviru
diseas
associ
pneumonia
fatal
current
differ
drug
regimen
appli
clinic
studi
evidenc
efficaci
yet
scenario
initi
launch
world
health
organ
solidar
studi
compar
remdesivir
hydroxychloroquin
ritonavirlopinavir
ritonavirlopinavir
plu
regim
critic
import
priorit
use
activ
compound
alreadi
envis
solidar
trial
effect
antivir
therapi
usual
base
combin
therapi
tackl
distinct
step
viral
life
cycl
combin
may
critic
reduc
emerg
drug
resist
virus
potenti
antivir
activ
enhanc
chanc
improv
clinic
outcom
current
test
antivir
activ
differ
clinic
avail
compound
combin
assess
cellular
cytotox
viral
induc
cytopath
effect
vitro
mean
calcul
concentr
compound
combin
achiev
maxim
inhibitori
capac
ic
ongo
studi
aim
compar
current
avail
drug
possibl
combin
counteract
cytopath
effect
vitro
priorit
activ
provid
solid
evidencedriven
rational
inform
prospect
clinic
trial
strategi
circumscrib
compound
alreadi
approv
clinic
use
sinc
ideal
candid
enter
fast
track
clinic
trial
drug
select
criteria
first
focus
compound
current
test
clinic
trial
along
wellknown
hcv
proteas
inhibitor
well
inhibitor
suggest
potenti
activ
ongo
molecular
dock
studi
also
perform
inform
possibl
candid
could
repurpos
block
replic
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
present
result
experi
ongo
data
care
interpret
suffici
replic
studi
underway
becom
avail
yet
given
urgent
situat
face
fact
compound
test
alreadi
clinic
approv
report
ongo
experi
expedit
manner
scientif
commun
clearli
stress
limit
preliminari
data
addit
also
import
highlight
vitro
efficaci
alway
translat
clinic
efficaci
even
replic
studi
confirm
result
obtain
welldesign
control
clinic
trial
need
assess
safeti
efficaci
toler
antivir
treatment
combin
describ
herein
assess
antivir
activ
safeti
relev
anim
model
could
key
identifi
advanc
compound
highest
potenti
succeed
clinic
trial
thu
project
produc
list
effect
compound
proven
antivir
efficaci
vitro
halt
replic
focus
alreadi
clinic
approv
human
turn
inform
could
guid
futur
clinic
trial
offer
potenti
therapeut
benefit
individu
infect
entri
requir
viral
bind
spike
protein
activ
via
interact
cellular
receptor
cellular
proteas
hoffmann
et
al
mechan
favor
viral
intern
via
endocytosi
interfer
either
initi
process
proven
decreas
entri
infect
hoffmann
et
al
monteil
et
al
addit
accumul
endosom
cellular
cathepsin
also
prime
viral
spike
protein
cleavag
favor
viral
fusion
henc
first
test
compound
could
effect
viral
entri
impair
viralcel
fusion
tabl
given
wide
clinic
use
worldwid
first
confirm
inhibitori
effect
hydroxychloroquin
induc
cellular
cytotox
constant
concentr
stock
sequenc
upon
isol
access
id
gisaid
repositori
http
gisaidorg
mix
decreas
concentr
hydroxychloroquin
ad
vero
cell
control
druginduc
cytotox
vero
also
cultur
decreas
concentr
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
hydroxychloroquin
absenc
shown
fig
drug
abl
inhibit
viralinduc
cytopath
effect
red
line
concentr
cytotox
effect
drug
observ
grey
line
mean
concentr
drug
inhibit
cytotox
mean
ic
valu
result
align
previou
report
highlight
vitro
inhibitori
capac
chloroquin
deriv
wang
et
al
preliminari
benefit
observ
small
cohort
patient
gautret
et
al
confirm
ongo
largescal
random
solidar
trial
sinc
hydroxychloroquin
administ
combin
antibiot
azithromycin
gautret
et
al
induc
antivir
respons
bronchial
epitheli
cell
gielen
et
al
test
activ
compound
assay
howev
vero
model
azithromycin
show
antivir
effect
fig
combin
hydroxychloroquin
azithromycin
similar
activ
chloroquin
deriv
alon
fig
addit
fdaapprov
compound
previous
use
abrog
viral
entri
via
clathrinmedi
endocytosi
also
test
cytotox
assay
tabl
inde
clathrinmedi
endocytosi
one
potenti
mechan
hydroxychloroquin
may
exert
therapeut
effect
one
compound
amantadin
licens
influenza
viru
infect
treatment
parkinson
diseas
block
coat
pit
invagin
plasma
membran
phonphok
rosenth
addit
also
test
chlorpromazin
antipsychot
drug
inhibit
clathrinmedi
endocytosi
prevent
assembl
disassembl
clathrin
network
cellular
membran
endosom
wang
et
al
assess
antivir
efficaci
clathrin
inhibitor
find
promin
effect
partial
inhibit
amantadin
supp
fig
broad
cathepsin
bl
inhibitor
exert
activ
virus
cleav
cellular
cathepsin
upon
endosom
intern
case
ebola
viru
gielen
et
al
show
also
partial
inhibitori
activ
supp
fig
alreadi
describ
pseudotyp
virus
hoffmann
et
al
result
could
confirm
use
specif
cathepsin
b
inhibitor
due
drugassoci
toxic
import
highlight
none
cathepsin
inhibitor
approv
clinic
use
data
suggest
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
entri
partial
reli
clathrinmedi
endocytosi
cellular
cathepsin
cleav
viral
spike
protein
allow
viral
fusion
intern
endosom
howev
hydroxychloroquin
activ
much
potent
exert
amantadin
paramount
dissect
possibl
pathway
could
respons
potent
antivir
effect
hydroxychloroquin
fantini
et
al
upon
viral
intern
fuse
endosom
membran
trigger
viral
rna
releas
cytoplasm
polyprotein
translat
cleav
proteas
song
et
al
lead
format
rna
replicasetranscriptas
complex
drive
product
negativestrand
rna
via
replic
transcript
song
et
al
negativestrand
rna
drive
transcript
posit
rna
genom
translat
viral
nucleoprotein
assembl
viral
capsid
cytoplasm
song
et
al
capsid
bud
lumen
ergolgi
compart
virus
final
releas
extracellular
space
exocytosi
potenti
step
viral
cycl
suscept
target
differ
antivir
compound
search
antivir
first
focus
remdesivir
vitro
activ
viral
entri
remdesivir
broadspectrum
promis
antivir
drug
ebola
viru
mulangu
et
al
highli
pathogen
coronavirus
sarscov
merscov
sheahan
et
al
remdesivir
act
adenosin
analogu
incorpor
nascent
viral
rna
chain
result
prematur
termin
warren
et
al
given
clinic
safeti
proven
last
ebola
outbreak
remdesivir
actual
assay
solidar
trial
shown
efficaci
nonhuman
primat
anim
model
williamson
et
al
confirm
vitro
capac
inhibit
cytotox
concentr
cytotox
effect
drug
observ
fig
mean
ic
valu
drug
combin
hydroxychloroquin
howev
remdesivir
improv
antivir
effect
ad
alon
fig
yet
hydroxychloroquin
remdesivir
show
best
ic
valu
compound
test
screen
fig
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
also
assess
clinic
approv
proteas
inhibitor
potent
activ
howev
none
proteas
inhibitor
detail
tabl
show
remark
protect
cytotox
activ
infect
fig
darunavir
current
test
ongo
clinic
trial
show
partial
inhibitori
activ
although
concentr
cytotox
associ
supp
fig
note
revers
transcriptas
inhibitor
tenofovir
emtricitabin
combin
also
fail
show
antivir
effect
supp
also
assess
inhibitori
capac
hcv
proteas
inhibitor
broad
antivir
antiparasit
antimalari
antiinfluenza
antifung
compound
tabl
among
favipiravir
show
partial
inhibitori
activ
nontox
concentr
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
current
assess
antivir
activ
clinic
approv
compound
may
exert
antivir
effect
alon
combin
combin
therapi
could
provid
better
antivir
potenc
reduc
viral
resist
appear
far
test
compound
combin
confirm
effect
hydroxychloroquin
remdesivir
potent
antivir
screen
increas
potenc
combin
remdesivir
suitabl
oral
deliveri
poor
hepat
stabil
would
like
result
almost
complet
firstpass
clearanc
ema
therefor
requir
intraven
inject
complic
use
hydroxychloroquin
hand
oral
avail
shown
gener
serum
level
safe
dosag
human
mechan
action
remdesivir
clear
futur
work
address
hydroxychloroquin
actual
interf
viral
replic
inform
could
key
identifi
new
prophylact
therapeut
candid
antivir
identifi
herein
limit
potenc
cytopath
effect
lopinavir
tipranavir
although
worth
mention
inhibit
concentr
identifi
reachabl
human
plasma
walmsley
et
al
result
warrant
assess
clinic
avail
drug
necessari
increas
current
arsen
infect
ongo
studi
continu
provid
result
soon
becom
avail
data
present
herein
interpret
caution
clearli
understand
limit
vitro
model
even
enough
replic
assay
prove
reproduc
ic
valu
drug
obtain
vitro
may
reflect
could
happen
vivo
upon
infect
thu
next
goal
confirm
data
adequ
anim
model
soon
enough
potent
candid
combin
priorit
studi
turn
result
could
provid
ration
basi
perform
futur
clinic
trial
infect
individu
also
preexposur
prophylaxi
strategi
could
avoid
novel
infect
prophylaxi
could
envis
popul
level
protect
vulner
group
implement
effect
vaccin
safe
develop
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
german
tria
pujol
hugtip
approv
studi
individu
involv
studi
gave
written
inform
consent
particip
eagl
medium
dmem
lonza
supplement
fetal
calf
serum
fc
euroclon
uml
penicillin
streptomycin
mm
glutamin
thermofish
scientif
nasopharyng
swab
collect
male
patient
give
inform
consent
treat
betaferon
dolquin
day
sampl
collect
swab
collect
ml
medium
deltaswab
reduc
viscos
store
use
vero
cell
cultur
cell
cultur
flask
cm
x
cell
overnight
prior
inocul
ml
process
sampl
h
co
afterward
ml
fcssupplement
dmem
suppli
cell
incub
h
supernat
harvest
centrifug
x
g
min
remov
cell
debri
store
cell
assess
daili
cytopath
effect
supernat
subject
viral
rna
extract
specif
rtqpcr
use
upe
rdrp
n
assay
corman
et
al
viral
rna
extract
directli
swab
sampl
isol
use
nucleospin
viru
kit
machereynagel
duren
germani
transcrib
cdna
use
rt
reagent
kit
takara
japan
use
oligodt
random
hexam
accord
manufactur
protocol
dna
process
nextera
kit
illumina
load
illumina
pairedend
sequenc
miseq
sequenc
platform
sequenc
read
qualiti
filter
map
coronaviru
refer
use
tool
langmead
et
al
consensu
genom
sequenc
call
result
align
median
coverag
use
samtool
li
et
al
genom
sequenc
deposit
gisaid
repositori
http
gisaidorg
access
id
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
antivir
compound
complet
list
compound
use
studi
vendor
shown
tabl
drug
use
concentr
rang
nm
serial
dilut
two
drug
combin
one
ad
concentr
rang
nm
serial
dilut
increas
concentr
antivir
compound
ad
vero
cell
togeth
tcid
ml
concentr
achiev
cytopath
effect
nonexpos
cell
use
neg
control
infect
order
detect
drugassoci
cytotox
effect
vero
cell
equal
cultur
presenc
increas
drug
concentr
absenc
viru
cytopath
cytotox
effect
viru
drug
measur
day
post
infect
use
celltiterglo
luminesc
cell
viabil
assay
promega
luminesc
measur
fluoroskan
ascent
fl
luminomet
thermofish
scientif
adjust
nonlinear
fit
regress
model
calcul
fourparamet
logist
curv
variabl
slope
cell
expos
viru
use
neg
control
infect
set
viabil
use
normal
data
calcul
percentag
cytopath
effect
analys
figur
gener
graphpad
prism
softwar
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
tabl
tabl
antivir
test
studi
classifi
depend
potenti
activ
viral
entri
na
activ
tbd
determin
nonlinear
fit
variabl
respons
curv
one
experi
two
replic
shown
red
line
cytotox
effect
vero
cell
expos
decreas
concentr
drug
absenc
viru
also
shown
grey
line
cytotox
effect
vero
cell
expos
fix
concentr
presenc
decreas
concentr
proteas
inhibitor
drug
use
concentr
rang
nm
nonlinear
fit
variabl
respons
curv
one
experi
two
replic
shown
red
line
exclud
data
drug
concentr
associ
toxic
cytotox
effect
vero
cell
expos
decreas
concentr
drug
absenc
viru
also
shown
grey
line
inhibitor
cytotox
effect
vero
cell
expos
fix
concentr
presenc
decreas
concentr
revers
transcriptas
inhibitor
drug
use
concentr
rang
nm
nonlinear
fit
variabl
respons
curv
one
experi
two
replic
shown
red
line
cytotox
effect
vero
cell
expos
decreas
concentr
drug
absenc
viru
also
shown
grey
line
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
